Gucalp A, et al. - This study was designed to test the hypothesis that treatment with docosahexaenoic acid (DHA, an omega-3 fatty acid, with anti-inflammatory properties) would reduce the expression of proinflammatory genes and aromatase, the rate-limiting enzyme for estrogen biosynthesis, in benign breast tissue of overweight/obese women. DHA was given for 12 weeks to overweight/obese women with a history of stage I–III breast cancer, DCIS/LCIS, Paget's disease, or proliferative benign breast disease. Study participants overall well-tolerated DHA treatment. Although compliance was confirmed, no changes were observed in the levels of prespecified biomarkers in the breast after treatment with DHA vs placebo.